Tirzepatide/Niacinamide 2mL vial — Class II drug recall D-0040-2027
Ongoing recall by Houston Rx LLC, reported 2026-10-21, distributed nationwide. Lack of assurance of sterility.
| Recall number | D-0040-2027 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Houston Rx LLC, Houston, TX, United States |
| Recall initiated | 2026-09-25 |
| Classified | 2026-10-13 |
| Reported by FDA | 2026-10-21 |
| Distributed | Nationwide (US) |
| Quantity | 64 vials |
| Reason classes | sterility |
| Lot numbers | TZN-080326-20/2-2 |
| Expiration dates | 2026-12-01 |
Product
Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032.
Reason for recall
Lack of assurance of sterility.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0040-2027. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-10-27. Not affiliated with or endorsed by FDA. Not medical or legal advice.